Second line immune checkpoint inhibition in urothelial cancer
Transl Androl Urol
.
2019 Oct;8(5):414-420.
doi: 10.21037/tau.2019.09.18.
Authors
Kilian M Gust
1
,
Mohammad Abufaraj
2
,
David D'Andrea
1
,
Marco Moschini
3
,
Francesco Soria
4
,
Shahrokh F Shariat
1
5
6
7
8
Affiliations
1
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
2
Department of Special Surgery, University of Jordan, Amman, Jordan.
3
Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.
4
Division of Urology, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy.
5
Department of Urology, Weill Cornell Medical College, New York, NY, USA.
6
Department of Urology, University of Texas Southwestern, Dallas, TX, USA.
7
Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
8
Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
PMID:
31807418
PMCID:
PMC6842776
DOI:
10.21037/tau.2019.09.18
No abstract available
Publication types
Editorial
Comment